Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Qianglidingxuan Tablets in the Treatment of Mild to Moderate Essential Hypertension With Hyperactivity of Liver Yang

NCT05521282 is registered in ClinicalTrials.gov with Guang'anmen Hospital of China Academy of Chinese Medical Sciences as lead sponsor.

NCT NCT05521282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05521282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Qianglidingxuan Tablets in the Treatment of Mild to Moderate Essential Hypertension With Hyperactivity of Liver Yang
Lead sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Phase
Phase 4
Overall status
Completed
Start date
March 9, 2021
Completion date
June 30, 2022
Enrollment
269 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, medicine, chinese traditional